Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-10.65	-8.36	-7.32
Depreciation & Amortization	0	0	0
Other Amortization	-	0.01	0.07
Stock-Based Compensation	1.42	0.71	1.01
Other Operating Activities	-0	3.96	4.26
Change in Accounts Payable	1.34	-0.24	0.44
Change in Other Net Operating Assets	0.54	0.38	0.22
Operating Cash Flow	-7.36	-3.53	-1.31
Capital Expenditures	-0.01	-0	-0
Investing Cash Flow	-0.01	-0	-0
Total Debt Issued	-	-	1.34
Short-Term Debt Repaid	-	-0.25	-
Total Debt Repaid	-	-0.25	-
Net Debt Issued (Repaid)	-	-0.25	1.34
Issuance of Common Stock	5.14	12.15	0.01
Other Financing Activities	3.84	-	-
Financing Cash Flow	8.98	11.9	1.35
Net Cash Flow	1.62	8.37	0.04
Free Cash Flow	-7.36	-3.53	-1.32
Free Cash Flow Per Share	-6.04	-3.93	-2.50
Levered Free Cash Flow	-3.56	-3.92	-
Unlevered Free Cash Flow	-3.56	-3.92	-
Change in Net Working Capital	-1.87	-0.14	-

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q